Cristina Gómez-Ayerbe
Research Interests
Cristina Gómez-Ayerbe has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Jesús Santos
Infectious Diseases Unit, Hospital Universitario Virgen de la Victoria (Málaga)
3 shared publications - Carmen Hidalgo-Tenorio
Affiliation Unit of Infectious Diseases, Hospital Universitario Virgen de las Nievesl, IBS-Granada, UGR, Granada, Spain
2 shared publications Jesús Santos
Hospital Virgen de La Victoria e IBIMA, Málaga, Spain
2 shared publications- Julián Olalla
Hospital Costa del Sol, Marbella, Spain
2 shared publications Rosario Palacios
Hospital Virgen de La Victoria e IBIMA, Málaga, Spain
2 shared publications- Rosario Palacios
Infectious Diseases Unit, Hospital Virgen de la Victoria , Málaga
2 shared publications
Latest Publications
- 28 October 2026
- Published by SAGE Publications in International Journal of STD & AIDS
Sexualized drug use and high-risk behaviors among men who have sex with men, transgender women, and gender-diverse individuals in Andalusia
Background: Sexualized drug is increasingly recognized as a health issue among gay, bisexual, and other men who have sex with men (GBMSM), transgender women and gender-diverse individuals. However, regional data remain scarce. This study aimed to characterize sexualized drug use in these populations in Andalusia, Spain, and explore associated sexual behaviors, outcomes, and professional perspectives relevant to healthcare organization. Methods: A cross-sectional study was conducted in Andalusia between December 2024 and May 2025 using two anonymous, self-administered surveys: one targeting individuals who engage in sexualized drug use, and the other targeting professionals involved in its prevention and care. Descriptive analyses were performed. Results: Of 159 completed and analyzed questionnaires, 148 participants reported drug use in a sexual context. Among participants reporting sexualized drug use (148/159), 65% reported a previous STI. In the chemsex subgroup ( n = 110), 78% reported long-lasting sexual episodes, 64% reported >25 sexual partners annually and 95% reported engaging in condomless sex. Among professionals ( n = 235), only 40% had received chemsex-specific training, and 94% reported insufficient multidisciplinary coordination. Conclusions: Sexualized drug use is an important public health concern. These findings support integrated sexual health, mental health and substance-use services, alongside professional training and coordinated care pathways.
- 28 October 2026
- Published by SAGE Publications in International Journal of STD & AIDS
Sexualized drug use and high-risk behaviors among men who have sex with men, transgender women, and gender-diverse individuals in Andalusia
Background: Sexualized drug is increasingly recognized as a health issue among gay, bisexual, and other men who have sex with men (GBMSM), transgender women and gender-diverse individuals. However, regional data remain scarce. This study aimed to characterize sexualized drug use in these populations in Andalusia, Spain, and explore associated sexual behaviors, outcomes, and professional perspectives relevant to healthcare organization. Methods: A cross-sectional study was conducted in Andalusia between December 2024 and May 2025 using two anonymous, self-administered surveys: one targeting individuals who engage in sexualized drug use, and the other targeting professionals involved in its prevention and care. Descriptive analyses were performed. Results: Of 159 completed and analyzed questionnaires, 148 participants reported drug use in a sexual context. Among participants reporting sexualized drug use (148/159), 65% reported a previous STI. In the chemsex subgroup ( n = 110), 78% reported long-lasting sexual episodes, 64% reported >25 sexual partners annually and 95% reported engaging in condomless sex. Among professionals ( n = 235), only 40% had received chemsex-specific training, and 94% reported insufficient multidisciplinary coordination. Conclusions: Sexualized drug use is an important public health concern. These findings support integrated sexual health, mental health and substance-use services, alongside professional training and coordinated care pathways.
- Open Access
- 16 December 2025
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (1)
Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis
- 16 December 2025
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (1)
Open AccessAbsence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis
- Open Access
- 21 March 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (4)
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
Background: Prior analyses suggest that the nucleoside reverse transcriptase inhibitor (NRTI) abacavir (ABC), but not tenofovir (TFV), is associated with a 2-fold increase in the hazard of myocardial infarction. the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is ideally suited to evaluate the role of ABC and the TFV backbones, tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), in major adverse cardiovascular events (MACE). Methods: We compared hazard of first MACE among people living with human immunodeficiency virus (HIV) at low-to-moderate cardiovascular risk using ABC (n = 883), TAF (n = 957), and TDF (n = 4274) at entry. Overlap weights balanced biasing factors, including age, sex at birth, atherosclerotic cardiovascular disease risk, CD4 count, estimated glomerular filtration rate, and anchor antiretroviral therapy. Associations between entry NRTI and MACEs were estimated using a marginal Cox proportional hazards model. Change of NRTI, or “switching,” was common during follow-up. Additional associations were estimated by further censoring at first switch and applying time-updated inverse probability of censoring weighting (IPCW). Results: Baseline-adjusted associations suggest clinically relevant increases in hazard of first MACE for ABC versus TAF (hazard ratio [HR], 1.5 [95% confidence interval {CI}, .9–2.3]) and ABC versus TDF (HR, 1.4 [95% CI, .9–2.1]), but not TAF versus TDF (HR, 0.9 [95% CI, .6–1.5]). With censoring at switch, HRs increased to 1.6 (95% CI, .9–2.7) for ABC versus TAF, 2.0 (95% CI, 1.2–3.4) for ABC versus TDF, and 1.2 (95% CI, .7–2.2) for TAF versus TDF. The largest HR observed was for ABC versus TDF and myocardial infarction (IPCW HR, 3.5 [95% CI, 1.3–9.4]). Conclusions: Antiretroviral therapies with ABC backbones are associated with an increase in MACE compared to TFV backbones among people living with HIV at low-to-moderate cardiovascular risk. Clinical Trials Registration: NCT02344290.
- 21 March 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (4)
Open AccessCardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
Background: Prior analyses suggest that the nucleoside reverse transcriptase inhibitor (NRTI) abacavir (ABC), but not tenofovir (TFV), is associated with a 2-fold increase in the hazard of myocardial infarction. the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is ideally suited to evaluate the role of ABC and the TFV backbones, tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), in major adverse cardiovascular events (MACE). Methods: We compared hazard of first MACE among people living with human immunodeficiency virus (HIV) at low-to-moderate cardiovascular risk using ABC (n = 883), TAF (n = 957), and TDF (n = 4274) at entry. Overlap weights balanced biasing factors, including age, sex at birth, atherosclerotic cardiovascular disease risk, CD4 count, estimated glomerular filtration rate, and anchor antiretroviral therapy. Associations between entry NRTI and MACEs were estimated using a marginal Cox proportional hazards model. Change of NRTI, or “switching,” was common during follow-up. Additional associations were estimated by further censoring at first switch and applying time-updated inverse probability of censoring weighting (IPCW). Results: Baseline-adjusted associations suggest clinically relevant increases in hazard of first MACE for ABC versus TAF (hazard ratio [HR], 1.5 [95% confidence interval {CI}, .9–2.3]) and ABC versus TDF (HR, 1.4 [95% CI, .9–2.1]), but not TAF versus TDF (HR, 0.9 [95% CI, .6–1.5]). With censoring at switch, HRs increased to 1.6 (95% CI, .9–2.7) for ABC versus TAF, 2.0 (95% CI, 1.2–3.4) for ABC versus TDF, and 1.2 (95% CI, .7–2.2) for TAF versus TDF. The largest HR observed was for ABC versus TDF and myocardial infarction (IPCW HR, 3.5 [95% CI, 1.3–9.4]). Conclusions: Antiretroviral therapies with ABC backbones are associated with an increase in MACE compared to TFV backbones among people living with HIV at low-to-moderate cardiovascular risk. Clinical Trials Registration: NCT02344290.
- Open Access
- 25 October 2024
- Published by Wiley in HIV Medicine
- Vol. 26 (2) , 308-318
Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain
Objectives: We assessed the opinions of physicians caring for people with HIV (PWH) from the multicentre Spanish CoRIS cohort regarding the assessment of health‐related quality of life (HRQoL).Methods: We designed an online self‐administered questionnaire comprising 27 structured questions across four domains: (i) sociodemographic and clinical data; (ii) usefulness of measuring HRQoL; (iii) information, training and resource needed; and (iv) whether and how HRQoL should be measured. Physicians completed the questionnaire between April and June 2023.Results: Of 131 physicians surveyed [53.8% men, median age 52 years (interquartile range: 42–60)], 90.9% and 88.6% agreed that measuring HRQoL is useful for both PWH and medical decision‐making, respectively. However, 67.2% needed training on what HRQoL is and how to measure it, 79.4% required information on validated tools, and 80.9% felt that clinical guidelines are needed. Overall, 90.1% of physicians agreed that HRQoL should be measured among PWH. Most physicians (82.8%) supported using specific scales for PWH, with 74.1% recommending annual measurement, 49.1% suggesting that nurses from HIV units conduct the assessments, and 43.1% favouring personal interviews during medical visits. At the time of the survey, 55.3% of physicians did not measure HRQoL in any patients due to time or resource constraints (75.8%).Conclusions: Despite the recognized importance of HRQoL measurement in PWH, Spanish physicians encounter barriers such as time constraints and limited resources. Developing clear guidelines, using tailored scales, and integrating digital tools along with multidisciplinary support could enhance routine HRQoL assessments and improve patient‐centred care.
- 25 October 2024
- Published by Wiley in HIV Medicine
- Vol. 26 (2) , 308-318
Open AccessShould we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain
Objectives: We assessed the opinions of physicians caring for people with HIV (PWH) from the multicentre Spanish CoRIS cohort regarding the assessment of health‐related quality of life (HRQoL).Methods: We designed an online self‐administered questionnaire comprising 27 structured questions across four domains: (i) sociodemographic and clinical data; (ii) usefulness of measuring HRQoL; (iii) information, training and resource needed; and (iv) whether and how HRQoL should be measured. Physicians completed the questionnaire between April and June 2023.Results: Of 131 physicians surveyed [53.8% men, median age 52 years (interquartile range: 42–60)], 90.9% and 88.6% agreed that measuring HRQoL is useful for both PWH and medical decision‐making, respectively. However, 67.2% needed training on what HRQoL is and how to measure it, 79.4% required information on validated tools, and 80.9% felt that clinical guidelines are needed. Overall, 90.1% of physicians agreed that HRQoL should be measured among PWH. Most physicians (82.8%) supported using specific scales for PWH, with 74.1% recommending annual measurement, 49.1% suggesting that nurses from HIV units conduct the assessments, and 43.1% favouring personal interviews during medical visits. At the time of the survey, 55.3% of physicians did not measure HRQoL in any patients due to time or resource constraints (75.8%).Conclusions: Despite the recognized importance of HRQoL measurement in PWH, Spanish physicians encounter barriers such as time constraints and limited resources. Developing clear guidelines, using tailored scales, and integrating digital tools along with multidisciplinary support could enhance routine HRQoL assessments and improve patient‐centred care.
- 20 September 2024
- Published by Elsevier in Enfermedades Infecciosas y Microbiología Clínica
- Vol. 42 (8) , 399-400
Acute and recent hepatitis C virus (HCV) infections in men having sex with men (MSM): Is the test&treat strategy fundamental to reduce the incidence in this population?
- 20 September 2024
- Published by Elsevier in Enfermedades Infecciosas y Microbiología Clínica
- Vol. 42 (8) , 399-400
Acute and recent hepatitis C virus (HCV) infections in men having sex with men (MSM): Is the test&treat strategy fundamental to reduce the incidence in this population?
- Open Access
- 20 February 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (8)
The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers
BACKGROUND: Persistent controllers (PCs) maintain antiretroviral-free HIV-1 control indefinitely over time, while transient controllers (TCs) eventually lose virological control. It is essential to characterize the quality of the HIV reservoir in terms of these phenotypes in order to identify the factors that lead to HIV progression and to open new avenues toward an HIV cure. METHODS: The characterization of HIV-1 reservoir from peripheral blood mononuclear cells was performed using next-generation sequencing techniques, such as full-length individual and matched integration site proviral sequencing (FLIP-Seq; MIP-Seq). RESULTS: PCs and TCs, before losing virological control, presented significantly lower total, intact, and defective proviruses compared with those of participants on antiretroviral therapy (ART). No differences were found in total and defective proviruses between PCs and TCs. However, intact provirus levels were lower in PCs compared with TCs; indeed the intact/defective HIV-DNA ratio was significantly higher in TCs. Clonally expanded intact proviruses were found only in PCs and located in centromeric satellite DNA or zinc-finger genes, both associated with heterochromatin features. In contrast, sampled intact proviruses were located in permissive genic euchromatic positions in TCs. CONCLUSIONS: These results suggest the need for, and can give guidance to, the design of future research to identify a distinct proviral landscape that may be associated with the persistent control of HIV-1 without ART. FUNDING: Instituto de Salud Carlos III (FI17/00186, FI19/00083, MV20/00057, PI18/01532, PI19/01127 and PI22/01796), Gilead Fellowships (GLD22/00147). NIH grants AI155171, AI116228, AI078799, HL134539, DA047034, MH134823, amfAR ARCHE and the Bill and Melinda Gates Foundation.
- 20 February 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (8)
Open AccessThe HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers
BACKGROUND: Persistent controllers (PCs) maintain antiretroviral-free HIV-1 control indefinitely over time, while transient controllers (TCs) eventually lose virological control. It is essential to characterize the quality of the HIV reservoir in terms of these phenotypes in order to identify the factors that lead to HIV progression and to open new avenues toward an HIV cure. METHODS: The characterization of HIV-1 reservoir from peripheral blood mononuclear cells was performed using next-generation sequencing techniques, such as full-length individual and matched integration site proviral sequencing (FLIP-Seq; MIP-Seq). RESULTS: PCs and TCs, before losing virological control, presented significantly lower total, intact, and defective proviruses compared with those of participants on antiretroviral therapy (ART). No differences were found in total and defective proviruses between PCs and TCs. However, intact provirus levels were lower in PCs compared with TCs; indeed the intact/defective HIV-DNA ratio was significantly higher in TCs. Clonally expanded intact proviruses were found only in PCs and located in centromeric satellite DNA or zinc-finger genes, both associated with heterochromatin features. In contrast, sampled intact proviruses were located in permissive genic euchromatic positions in TCs. CONCLUSIONS: These results suggest the need for, and can give guidance to, the design of future research to identify a distinct proviral landscape that may be associated with the persistent control of HIV-1 without ART. FUNDING: Instituto de Salud Carlos III (FI17/00186, FI19/00083, MV20/00057, PI18/01532, PI19/01127 and PI22/01796), Gilead Fellowships (GLD22/00147). NIH grants AI155171, AI116228, AI078799, HL134539, DA047034, MH134823, amfAR ARCHE and the Bill and Melinda Gates Foundation.
- 7 September 2022
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 33 (13) , 1119-1123
Weight changes after first-line antiretroviral initiation in a cohort of HIV-positive patients in Southern Spain (CAPOTA study)
Background: Obesity among persons living with HIV (PLWH) has increased and weight gain after antiretroviral therapy (ART) can lead to metabolic disorders and impact survival. Our objective was to analyze weight and metabolic changes in HIV näive patients after 48 weeks of ART. Methods: Observational, retrospective, multicentered cohort study comprising naïve-patients who started tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat (TAF/FTC/EVG/c) or abacavir/lamivudine/dolutegravir (ABC/3TC/DTG), with no change in treatment for 48 weeks. Clinical and metabolic parameters were collected at baseline and week-48. Statistical program used was SPSS 21.0.0. Results: The study included 329 participants from 6 hospitals. Participants were 89% male and 10% had AIDS diagnosis. Median age was 35 (IQR 27–43) years. Median baseline CD4 count was 417 (IQR 250–569) cell/mm3 and HIV viral load 4.65 (IQR 4.21–5.18) log10 copies/ml. Baseline median weight was 70 (IQR 62–79) kg, body mass index 23.4 (IQR 21.2–26.0) kg/m2; 22.7% overweight and 6.4% obese. ART regimens: ABC/3TC/DTG (196), TAF/FTC/EVG/c (133). Baseline characteristics were similar in both ART groups. Average weight gain at week-48 was 2.9 (SD 5.5) kg ( p < 0.0001) with no differences between both groups. There was an increase in obesity (6.4%–8%; p < 0.003) and overweight (22.7%–28.9%; p < 0.0001). Weight increase was associated with AIDS: OR 3.05 (95%; CI 1.009–9.22), p = 0.048; and lower baseline weight: OR 1.032 (95% CI 1.009–1.05), p = 0.006. Conclusions: After ART initiation patients gain weight regardless of the regimen they take. Weight gain is associated with AIDS and the use of TAF/FTC/EVG/c.
- 7 September 2022
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 33 (13) , 1119-1123
Weight changes after first-line antiretroviral initiation in a cohort of HIV-positive patients in Southern Spain (CAPOTA study)
Background: Obesity among persons living with HIV (PLWH) has increased and weight gain after antiretroviral therapy (ART) can lead to metabolic disorders and impact survival. Our objective was to analyze weight and metabolic changes in HIV näive patients after 48 weeks of ART. Methods: Observational, retrospective, multicentered cohort study comprising naïve-patients who started tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat (TAF/FTC/EVG/c) or abacavir/lamivudine/dolutegravir (ABC/3TC/DTG), with no change in treatment for 48 weeks. Clinical and metabolic parameters were collected at baseline and week-48. Statistical program used was SPSS 21.0.0. Results: The study included 329 participants from 6 hospitals. Participants were 89% male and 10% had AIDS diagnosis. Median age was 35 (IQR 27–43) years. Median baseline CD4 count was 417 (IQR 250–569) cell/mm3 and HIV viral load 4.65 (IQR 4.21–5.18) log10 copies/ml. Baseline median weight was 70 (IQR 62–79) kg, body mass index 23.4 (IQR 21.2–26.0) kg/m2; 22.7% overweight and 6.4% obese. ART regimens: ABC/3TC/DTG (196), TAF/FTC/EVG/c (133). Baseline characteristics were similar in both ART groups. Average weight gain at week-48 was 2.9 (SD 5.5) kg ( p < 0.0001) with no differences between both groups. There was an increase in obesity (6.4%–8%; p < 0.003) and overweight (22.7%–28.9%; p < 0.0001). Weight increase was associated with AIDS: OR 3.05 (95%; CI 1.009–9.22), p = 0.048; and lower baseline weight: OR 1.032 (95% CI 1.009–1.05), p = 0.006. Conclusions: After ART initiation patients gain weight regardless of the regimen they take. Weight gain is associated with AIDS and the use of TAF/FTC/EVG/c.
- 23 July 2021
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 32 (13) , 1257-1260
Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic?
Early diagnosis and treatment of incident cases of hepatitis C virus (HCV) infection is fundamental to eliminate HCV in HIV-positive patients. From January 2016 to December 2019, we attended 40 episodes of acute HCV infection (AHC) in 35 subjects (9 reinfections) who were coinfected with HIV. The patients were treated with direct-acting antiviral agents (DAAs) in seven hospitals in Andalusia, Spain. All were men who have sex with men (MSM), mean age was 42.9 (±8.3) years and median time of HIV infection was 46.6 months (IQR: 20.4–67.2). All received antiretroviral therapy and had undetectable HIV viral load (except 2 with 65 and 68 copies/mL); median CD4 count was 632 cells/mm3 (IQR: 553–896). Over half (74.3%) also had another concomitant sexually transmitted infection, syphilis (48.6%) being the most common. AHC was asymptomatic in 32 cases (80%). Genotypic distribution was G1a 65%, G4 32.5% and G1b 3%. Median time to DAA was 6 weeks (IQR: 4.3–18.3) and median baseline HCV RNA was 6.1 Log (IQR: 5.6–6.5). DAA regimens were SOF/LDV (19 episodes), SOF/VEL (14), ELB/GZV (5) and GLP/PIB (2). All presented sustained viral response and none discontinued due to adverse effects. In conclusion, early treatment with DAA in AHC patients proved effective and safe. It could be an excellent strategy to eliminate HCV infection in HIV-coinfected MSM.
- 23 July 2021
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 32 (13) , 1257-1260
Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic?
Early diagnosis and treatment of incident cases of hepatitis C virus (HCV) infection is fundamental to eliminate HCV in HIV-positive patients. From January 2016 to December 2019, we attended 40 episodes of acute HCV infection (AHC) in 35 subjects (9 reinfections) who were coinfected with HIV. The patients were treated with direct-acting antiviral agents (DAAs) in seven hospitals in Andalusia, Spain. All were men who have sex with men (MSM), mean age was 42.9 (±8.3) years and median time of HIV infection was 46.6 months (IQR: 20.4–67.2). All received antiretroviral therapy and had undetectable HIV viral load (except 2 with 65 and 68 copies/mL); median CD4 count was 632 cells/mm3 (IQR: 553–896). Over half (74.3%) also had another concomitant sexually transmitted infection, syphilis (48.6%) being the most common. AHC was asymptomatic in 32 cases (80%). Genotypic distribution was G1a 65%, G4 32.5% and G1b 3%. Median time to DAA was 6 weeks (IQR: 4.3–18.3) and median baseline HCV RNA was 6.1 Log (IQR: 5.6–6.5). DAA regimens were SOF/LDV (19 episodes), SOF/VEL (14), ELB/GZV (5) and GLP/PIB (2). All presented sustained viral response and none discontinued due to adverse effects. In conclusion, early treatment with DAA in AHC patients proved effective and safe. It could be an excellent strategy to eliminate HCV infection in HIV-coinfected MSM.
- Open Access
A Pandemic within Other Pandemics. When a Multiple Infection of a Host Occurs: SARS-CoV-2, HIV and Mycobacterium tuberculosis
By the middle of 2021, we are still immersed in the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The concurrence of this new pandemic in regions where human immunodeficiency virus (HIV) and tuberculosis (TB) infections possess the same epidemiological consideration, has arisen concerns about the prognosis, clinical management, symptomatology, and treatment of patients with triple infection. At the same time, healthcare services previously devoted to diagnosis and treatment of TB and HIV are being jeopardized by the urgent need of resources and attention for COVID-19 patients. The aim of this review was to collect any article considering the three conditions (HIV, TB, and SARS-CoV-2), included in PubMed/Medline and published in the English language since the beginning of the COVID-19 pandemic. We focused on detailed descriptions of the unusual cases describing the three co-infections. Eighty-four out of 184 publications retrieved met our inclusion criteria, but only three of them reported cases (five in total) with the three concomitant infections. The clinical evolution, management, and therapy of all of them were not different from mild/severe cases with exclusive COVID-19; the outcome was not worse either, with recovery for the five patients. Cases of patients with COVID-19 besides HIV and TB infections are scarce in literature, but studies deliberately embracing the triple infection as a priori inclusion criterion should be carried out in order to provide a complete understanding of joint influence.
Open AccessA Pandemic within Other Pandemics. When a Multiple Infection of a Host Occurs: SARS-CoV-2, HIV and Mycobacterium tuberculosis
By the middle of 2021, we are still immersed in the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The concurrence of this new pandemic in regions where human immunodeficiency virus (HIV) and tuberculosis (TB) infections possess the same epidemiological consideration, has arisen concerns about the prognosis, clinical management, symptomatology, and treatment of patients with triple infection. At the same time, healthcare services previously devoted to diagnosis and treatment of TB and HIV are being jeopardized by the urgent need of resources and attention for COVID-19 patients. The aim of this review was to collect any article considering the three conditions (HIV, TB, and SARS-CoV-2), included in PubMed/Medline and published in the English language since the beginning of the COVID-19 pandemic. We focused on detailed descriptions of the unusual cases describing the three co-infections. Eighty-four out of 184 publications retrieved met our inclusion criteria, but only three of them reported cases (five in total) with the three concomitant infections. The clinical evolution, management, and therapy of all of them were not different from mild/severe cases with exclusive COVID-19; the outcome was not worse either, with recovery for the five patients. Cases of patients with COVID-19 besides HIV and TB infections are scarce in literature, but studies deliberately embracing the triple infection as a priori inclusion criterion should be carried out in order to provide a complete understanding of joint influence.
- Open Access
- 4 March 2021
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 34 (2) , 167-168
Paratyphoid fever two months after a trip to India
- 4 March 2021
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 34 (2) , 167-168
Open AccessParatyphoid fever two months after a trip to India